Delivery Order SPE2DB24D2106-SPE2DB25FAULK

Award Date 1/28/25
Potential Completion Date 1/29/25
Potential Value $2.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a delivery order contract (SPE2DB20D6037|SPE2DB25FTUE9) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,051.36 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award, valued at $2,312.08, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order under the DLA's SPE2DB program, an indefinite delivery contract (IDC) valued up to $499,999,999 that runs through December 31, 2025. This single-award IDC allows the DLA to issue delivery orders for a comprehensive range of...
This federal contract award issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract is a firm fixed-price delivery order with a ceiling value of $1,631.03 and a completion date of October 29, 2024. DMS Pharmaceutical Group Inc. is the prime contractor and this order is issued under a larger $499,999,999 Indefinite Delivery Contract (IDC) the company...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,451.98 firm fixed-price delivery order is for the supply of 120 ml bottles of the prescription medication Quillivant XR (25 mg/5 ml suspension). The award is not associated with a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,973.05, is a firm fixed-price delivery order for Quillivant XR 25 mg/5 ml suspension, a pharmaceutical product. The contract has an ultimate completion date of December 5, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois, is a firm fixed-price delivery order under the SPE2DB program with the Defense Logistics Agency (DLA). The $1,883.83 award is for the medication Quillivant XR 25 mg/5 ml suspension, 120 ml, with a performance period ending on May 21, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a diverse portfolio of branded and...
The U.S. Defense Logistics Agency (DLA) awarded a $3,303.87 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business in Park Ridge, Illinois. The contract is for the supply of Quillivant XR 25 mg/5 mL suspension, a pharmaceutical product. This delivery order is part of a larger indefinite delivery contract valued up to $4,999,999 held by DMS Pharmaceutical Group with DLA, contract number SPE2DB24D2106, which allows DLA to issue delivery orders for a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,605.38 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The award is not associated with any set-aside designations. DMS Pharmaceutical Group holds a significant $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB25FAULK
    Delivery Order

This federal contract award, valued at $2,683.84, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Quillivant XR 25 mg/5 ml suspension, a pharmaceutical product.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.

Generated 4/29/25, 9:43 AM